LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Objective: A novel dual GIP and GLP-1 receptor agonist, LY3298176, was developed to determine whether the metabolic action of GIP adds to the established clinical benefits of selective GLP-1 receptor agonists in type 2 diabetes mellitus (T2DM). Methods: LY3298176 is a fatty acid modified peptide wit...

Full description

Bibliographic Details
Main Authors: Tamer Coskun, Kyle W. Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B. Bokvist, Xuewei Cui, Daniel A. Briere, Over Cabrera, William C. Roell, Uma Kuchibhotla, Julie S. Moyers, Charles T. Benson, Ruth E. Gimeno, David A. D'Alessio, Axel Haupt
Format: Article
Language:English
Published: Elsevier 2018-12-01
Series:Molecular Metabolism
Online Access:http://www.sciencedirect.com/science/article/pii/S2212877818309001

Internet

http://www.sciencedirect.com/science/article/pii/S2212877818309001

Similar Items